bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Authors: Luo Rongrong , Zhong Pei , Li Xiying , Cai Juan , Tao Yimin , Xiong Bangzhu , Zheng Hancheng , Zhang Zhishang , Tang Le , Yao Jiarui , Li Yingrui , Shi Yuankai , Han Xiaohong
Published: April 2023

AbstractBackground:
Early diagnosis is critical to lung adenocarcinoma patients’ survival but faces inadequacies in convenient early detection.
Methods:
We applied a comprehensive microarray of 130,000 peptides to detect “autoantibody signature” that is autoantibodies binding to mimotopes for early detection of stage 0–I LUAD. Plasma samples were collected from 147 early-stage lung adenocarcinoma (Early-LUAD), 108 benign lung disease (BLD), and 122 normal healthy controls (NHC). Clinical characteristics, low-dose CT (LDCT), and laboratory tests were incorporated into correlation analysis.
Results:
We identified 143 and 133 autoantibody signatures, distinguishing Early-LUAD from NHC/BLD in the discovery cohort. Autoantibody signatures significantly correlated with age, stage, tumor size, basophil count, and IgM level (P < 0.05). The random forest models based on differential autoantibody signatures displayed AUC of 0.92 and 0.87 to discern Early-LUAD from NHC/BLD in the validation cohort, respectively. Compared with LDCT, combining autoantibody signature and LDCT improved the positive predictive value from 50% to 78.33% (P = 0.049). In addition, autoantibody signatures displayed higher sensitivity of 72.4% to 81.0% compared with the combinational tumor markers (cyfra21.1, NSE, SCC, ProGRP) with a sensitivity of 22.4% (P = 0.000). Proteins matched by differential peptides were enriched in cancer-related PI3K/Akt, MAPK, and Wnt pathways. Overlaps between matched epitopes and autoantibody signatures illustrated the underlying engagement of autoantibodies in immune recognition.
Conclusions:
Collectively, autoantibody signatures identified by a high-throughput peptide microarray have the potential to detect Early-LUAD, which could assist LDCT to better diagnose Early-LUAD.
Impact:
Novel sensitive autoantibody signatures can adjuvant LDCT to better diagnose LUAD at very early stage.
Supplementary Table S1 from Reversal of Lactate and PD-1–mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer
Authors: Chaudagar Kiranj , Hieromnimon Hanna M. , Khurana Rimpi , Labadie Brian , Hirz Taghreed , Mei Shenglin , Hasan Raisa , Shafran Jordan , Kelley Anne , Apostolov Eva , Al-Eryani Ghamdan , Harvey Kate , Rameshbabu Srikrishnan , Loyd Mayme , Bynoe Kaela , Drovetsky Catherine , Solanki Ani , Markiewicz Erica , Zamora Marta , Fan Xiaobing , Schürer Stephan , Swarbrick Alex , Sykes David B. , Patnaik Akash
Published: April 2023

Supplementary Table S1. ADT + PI3Ki + PD-1 antibody leads to TAM activation within TME of PTEN/p53-deficient prostate tumors.
Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
Authors: Chavez Julio C. , Foss Francine M. , William Basem M. , Brammer Jonathan E. , Smith Sonali M. , Prica Anca , Zain Jasmine M. , Tuscano Joseph M. , Shah Harsh , Mehta-Shah Neha , Geethakumari Praveen Ramakrishnan , Wang Ben X. , Zantinge Stephanie , Wang Lisa , Zhang Ling , Boutrin Anmarie , Zhao Weiguang , Cheng Lily , Standifer Nathan , Hewitt Lisa , Enowtambong Enowmpey , Shao Weiping , Sharma Shringi , Carlesso Gianluca , Moscow Jeffrey A. , Siu Lillian L.
Published: April 2023

Supplemental Figure 3. Representative baseline pre-treatment tumor specimen of a patient with AITL (H&E, ICOS staining and CD3 staining by IHC)
Supplementary Table S2 from Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
Authors: Gulati Shuchi , Crist McKenzie , Riaz Muhammed Kashif , Takiar Vinita , Lehn Maria , Monroe Ilaina , Palackdharry Sarah , Kurtzweil Nicky , Jandarov Roman , Harun Nusrat , Wise-Draper Trisha M.
Published: April 2023

All treatment-related adverse events on trial
Supplementary Figure S7 from Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
Authors: Gulati Shuchi , Crist McKenzie , Riaz Muhammed Kashif , Takiar Vinita , Lehn Maria , Monroe Ilaina , Palackdharry Sarah , Kurtzweil Nicky , Jandarov Roman , Harun Nusrat , Wise-Draper Trisha M.
Published: April 2023

Supplementary Figures 7A, 7B and 7C Cetuximab enhances anti-tumor cytokines: Cytokine concentrations in the sample supernatants were determined by enzyme-linked immunosorbent assay (ELISA) using a Luminex assay (R&Dsystems, a bio-techne brand, Minneapolis, MN) according to the manufacturer's protocol. Cetuximab alone decreased pro-tumorigenic IL-6 levels and increased IP-10 suggesting an anti-tumor response (Supplementary Figure 7A and 7B); however, these cytokines were not significantly changed between responders (those with CR, PR, SD) and non-responders. The full panel of tested cytokines, shown in Supplementary Figure 7C.Abbreviations: CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NK: Natural Killer; IL: interleukin; IP: Interferon gamma inducible protein-10 (IP-10).
Supplementary Figure S6 from Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
Authors: Gulati Shuchi , Crist McKenzie , Riaz Muhammed Kashif , Takiar Vinita , Lehn Maria , Monroe Ilaina , Palackdharry Sarah , Kurtzweil Nicky , Jandarov Roman , Harun Nusrat , Wise-Draper Trisha M.
Published: April 2023

Supplementary Figure 6. Comparison of outcomes between patients that were p16 positive vs. negative A) Progression-free survival and B) Overall survival comparison
Supplementary Figure S4 from Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
Authors: Gulati Shuchi , Crist McKenzie , Riaz Muhammed Kashif , Takiar Vinita , Lehn Maria , Monroe Ilaina , Palackdharry Sarah , Kurtzweil Nicky , Jandarov Roman , Harun Nusrat , Wise-Draper Trisha M.
Published: April 2023

Supplementary Figure 4. Comparison of outcomes between patients treated with prior systemic therapies vs. not A) Progression-free survival and B) Overall survival comparison
Supplementary Figure S3 from Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
Authors: Gulati Shuchi , Crist McKenzie , Riaz Muhammed Kashif , Takiar Vinita , Lehn Maria , Monroe Ilaina , Palackdharry Sarah , Kurtzweil Nicky , Jandarov Roman , Harun Nusrat , Wise-Draper Trisha M.
Published: April 2023

Supplementary Figure 3: Comparison of outcomes between patients treated with prior chemotherapy vs. not A) Progression-free survival and B) Overall survival comparison
Supplementary Figure S2 from Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
Authors: Gulati Shuchi , Crist McKenzie , Riaz Muhammed Kashif , Takiar Vinita , Lehn Maria , Monroe Ilaina , Palackdharry Sarah , Kurtzweil Nicky , Jandarov Roman , Harun Nusrat , Wise-Draper Trisha M.
Published: April 2023

Consort diagram of the clinical trial.Abbreviations: OS, overall survival; PFS, progression-free survival
Supplementary Table S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Authors: Schoen Robert E. , Boardman Lisa A. , Cruz-Correa Marcia , Bansal Ajay , Kastenberg David , Hur Chin , Dzubinski Lynda , Kaufman Sharon F. , Rodriguez Luz M. , Richmond Ellen , Umar Asad , Szabo Eva , Salazar Andres , McKolanis John , Beatty Pamela , Pai Reetesh K. , Singhi Aatur D. , Jacqueline Camille M. , Bao Riuye , Diergaarde Brenda , McMurray Ryan P. , Strand Carrie , Foster Nathan R. , Zahrieh David M. , Limburg Paul J. , Finn Olivera J.
Published: April 2023

Baseline advanced adenoma characteristics
Supplementary Figure S2 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Authors: Schoen Robert E. , Boardman Lisa A. , Cruz-Correa Marcia , Bansal Ajay , Kastenberg David , Hur Chin , Dzubinski Lynda , Kaufman Sharon F. , Rodriguez Luz M. , Richmond Ellen , Umar Asad , Szabo Eva , Salazar Andres , McKolanis John , Beatty Pamela , Pai Reetesh K. , Singhi Aatur D. , Jacqueline Camille M. , Bao Riuye , Diergaarde Brenda , McMurray Ryan P. , Strand Carrie , Foster Nathan R. , Zahrieh David M. , Limburg Paul J. , Finn Olivera J.
Published: April 2023

MUC1 expression and immune infiltrate in baseline and recurrent adenoma pairs
Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Authors: Schober Sebastian Johannes , Schoening Caroline , Eck Jennifer , Middendorf Charlotte , Lutsch Julia , Knoch Pia , von Ofen Anna Josefine , Gassmann Hendrik , Thiede Melanie , Hauer Julia , Kolk Andreas , Mantwill Klaus , Gschwend Jürgen E. , Burdach Stefan E.G. , Nawroth Roman , Thiel Uwe , Holm Per Sonne
Published: April 2023

Supplemental Figure 4: Combination of XVir-N-31 and CDK4/6 inhibitor LEE011 induces an abscopal effect, induces monocyte infiltration and increases M1/M2 macrophage ratio in injected tumors.
Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Authors: Schober Sebastian Johannes , Schoening Caroline , Eck Jennifer , Middendorf Charlotte , Lutsch Julia , Knoch Pia , von Ofen Anna Josefine , Gassmann Hendrik , Thiede Melanie , Hauer Julia , Kolk Andreas , Mantwill Klaus , Gschwend Jürgen E. , Burdach Stefan E.G. , Nawroth Roman , Thiel Uwe , Holm Per Sonne
Published: April 2023

Supplemental Figure 3: Characterization of tumor-infiltrating T cells at the end of experiment (A673 xenografts).
Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Authors: Schober Sebastian Johannes , Schoening Caroline , Eck Jennifer , Middendorf Charlotte , Lutsch Julia , Knoch Pia , von Ofen Anna Josefine , Gassmann Hendrik , Thiede Melanie , Hauer Julia , Kolk Andreas , Mantwill Klaus , Gschwend Jürgen E. , Burdach Stefan E.G. , Nawroth Roman , Thiel Uwe , Holm Per Sonne
Published: April 2023

Supplemental Figure 2: Combination of XVir-N-31 (XVir) and CDK4/6 inhibitor LEE011 (LEE) increases viral replication and immunogenicity of xenografted EwS tumors in vivo.
Table S1 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Authors: Cole Alexander J. , Panesso-Gómez Santiago , Shah Jaynish S. , Ebai Tonge , Jiang Qi , Gumusoglu-Acar Ece , Bello Maya G. , Vlad Anda , Modugno Francesmary , Edwards Robert P. , Buckanovich Ronald J.
Published: April 2023

Supplementary Table 1. Primers used in this study.
Figure S3 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Authors: Cole Alexander J. , Panesso-Gómez Santiago , Shah Jaynish S. , Ebai Tonge , Jiang Qi , Gumusoglu-Acar Ece , Bello Maya G. , Vlad Anda , Modugno Francesmary , Edwards Robert P. , Buckanovich Ronald J.
Published: April 2023

Supplementary Figure 3. The effect of FST or taxol treatment ovarian cancer proliferation and FST secretion, and the ability of a FST neutralization antibody to inhibit FST's effect on proliferation. A. PT340 and PT412 cells were treated with 200 ng/mL FST for 72h before cell counts were performed. B (i) IHC images and (ii) FST+ cell bodies in OVSAHO tumor xenografts treated with or without taxol and stained with both Ki67 (Forangi Blue) and FST (Fast Red). C. Titer of the ability of the anti-FST neutralizing antibody to inhibit the effect of FST on cell growth.
Data from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Authors: Schober Sebastian Johannes , Schoening Caroline , Eck Jennifer , Middendorf Charlotte , Lutsch Julia , Knoch Pia , von Ofen Anna Josefine , Gassmann Hendrik , Thiede Melanie , Hauer Julia , Kolk Andreas , Mantwill Klaus , Gschwend Jürgen E. , Burdach Stefan E.G. , Nawroth Roman , Thiel Uwe , Holm Per Sonne
Published: April 2023

AbstractPurpose:
Ewing sarcoma (EwS) is a highly malignant pediatric tumor characterized by a non-T-cell-inflamed immune-evasive phenotype. When relapsed or metastasized, survival is poor, emphasizing the need for novel treatment strategies. Here, we analyze the novel combination approach using the YB-1-driven oncolytic adenovirus XVir-N-31 and CDK4/6 inhibition to augment EwS immunogenicity.
Experimental Design:
In vitro, viral toxicity, replication, and immunogenicity were studied in several EwS cell lines. In vivo tumor xenograft models with transient humanization were applied to evaluate tumor control, viral replication, immunogenicity, and dynamics of innate as well as human T cells after treatment with XVir-N-31 combined with CDK4/6 inhibition. Furthermore, immunologic features of dendritic cell maturation and T-cell-stimulating capacities were assessed.
Results:
The combination approach significantly increased viral replication and oncolysis in vitro, induced HLA-I upregulation, and IFNγ-induced protein 10 expression and enhanced maturation of monocytic dendritic cells with superior capacities to stimulate tumor antigen-specific T cells. These findings were confirmed in vivo showing tumor infiltration by (i) monocytes with antigen-presenting capacities and M1 macrophage marker genes, (ii) TReg suppression in spite of adenovirus infection, (iii) superior engraftment, and (iv) tumor infiltration by human T cells. Consequently, survival was improved over controls with signs of an abscopal effect after combination treatment.
Conclusions:
The joint forces of the YB-1-driven oncolytic adenovirus XVir-N-31 and CDK4/6 inhibition induce therapeutically relevant local and systemic antitumor effects. Innate as well as adaptive immunity against EwS is boosted in this preclinical setting, pointing toward high therapeutic potential in the clinic.
Data from Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer
Authors: Chaudagar Kiranj , Hieromnimon Hanna M. , Khurana Rimpi , Labadie Brian , Hirz Taghreed , Mei Shenglin , Hasan Raisa , Shafran Jordan , Kelley Anne , Apostolov Eva , Al-Eryani Ghamdan , Harvey Kate , Rameshbabu Srikrishnan , Loyd Mayme , Bynoe Kaela , Drovetsky Catherine , Solanki Ani , Markiewicz Erica , Zamora Marta , Fan Xiaobing , Schürer Stephan , Swarbrick Alexander , Sykes David B. , Patnaik Akash
Published: April 2023

Abstract
Purpose: PTEN loss-of-function occurs in ~50% of metastatic, castrate-resistant prostate cancer (mCRPC) patients, and associated with poor prognosis and responsiveness to standard-of-care therapies and immune checkpoint inhibitors. While PTEN loss-of-function hyperactivates PI3K signaling, combinatorial PI3K/AKT pathway and androgen deprivation therapy (ADT) has demonstrated limited anti-cancer efficacy in clinical trials. Here, we aimed to elucidate mechanism(s) of resistance to ADT/PI3K-AKT axis blockade, and to develop rational combinatorial strategies to effectively treat this molecular subset of mCRPC. Experimental design: Prostate-specific PTEN/p53-deficient genetically engineered mice (GEM) with established 150-200 mm3 tumors, as assessed by ultrasound, were treated with either ADT (degarelix), PI3K inhibitor (copanlisib), or anti-PD-1 antibody (aPD-1), as single agents or their combinations, and tumors were monitored by MRI and harvested for immune, transcriptomic and proteomic profiling, or ex vivo co-culture studies. Single-cell RNAseq on human mCRPC samples was performed using 10X Genomics platform. Results: Co-clinical trials in PTEN/p53-deficient GEM revealed that recruitment of PD-1-expressing tumor-associated macrophages (TAM) thwarts ADT/PI3Ki combination-induced tumor control. The addition of aPD-1 to ADT/PI3Ki combination led to TAM-dependent ~3-fold increase in anti-cancer responses. Mechanistically, decreased lactate production from PI3Ki-treated tumor cells suppressed histone lactylation within TAM, resulting in their anti-cancer phagocytic activation, which was augmented by ADT/aPD-1 treatment and abrogated by feedback activation of Wnt/β-catenin pathway. Single-cell RNA-sequencing analysis in mCRPC patient biopsy samples revealed a direct correlation between high glycolytic activity and TAM phagocytosis suppression. Conclusions: Immunometabolic strategies that reverse lactate and PD-1-mediated TAM immunosuppression, in combination with ADT, warrant further investigation in PTEN-deficient mCRPC patients.
Data from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma
Authors: Chavez Julio C. , Foss Francine M. , William Basem M. , Brammer Jonathan E. , Smith Sonali M. , Prica Anca , Zain Jasmine M. , Tuscano Joseph M. , Shah Harsh , Mehta-Shah Neha , Ramakrishnan Geethakumari Praveen Ramakrishnan. , Wang Ben X. , Zantinge Stephanie , Wang Lisa , Zhang Ling , Boutrin Anmarie , Zhao Weiguang , Cheng Lily , Standifer Nathan , Hewitt Lisa , Enowtambong Enowmpey , Shao Weiping , Sharma Shringi , Carlesso Gianluca , Moscow Jeffrey A. , Siu Lillian L.
Published: April 2023

Abstract
Purpose: Proliferation of T-follicular helper (TFH) CD4+ T-cells is a postulated pathogenic mechanism for T-cell non-Hodgkin’s lymphomas (T-NHL). The inducible T-cell costimulator (ICOS) is highly expressed by TFH, representing a potential target. MEDI-570 is a monoclonal antibody against ICOS, which eliminates ICOS+ cells in preclinical models. Patients and Methods: We report the safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of MEDI-570 in T-NHL. NCI-9930 is a phase I, first-in-human study of MEDI-570 in relapsed/refractory malignant T-NHL known to express ICOS. MEDI-570 was administered intravenously every 3 weeks for up to 12 cycles. Primary endpoints were safety, dose-limiting toxicities (DLT) and recommended phase 2 dose (RP2D). Secondary and exploratory endpoints included efficacy parameters and various correlative studies. This study is supported by the National Cancer Institute (NCT02520791). Results: Twenty-three patients were enrolled and received MEDI-570 at five dose levels (0.01 mg/kg to 3 mg/kg). Sixteen (70%) had angioimmunoblastic T-cell lymphoma (AITL); median age was 67 years (29 - 86) and the median prior lines of therapies was 3 (1 - 16). Most common grade 3 or 4 adverse events were decreased CD4+ T-cells (57%), lymphopenia (22%), anemia (13%), and infusion related reactions (9%). No DLTs were observed. The RP2D was determined at 3 mg/kg. Analysis of T-cell subsets showed reductions in CD4+ICOS+ T cells reflecting its effects on TFH cells. The response rate in AITL was 44%. Conclusions: MEDI-570 was well tolerated and showed promising clinical activity in refractory AITL. MEDI-570 resulted in sustained reduction of ICOS+ T lymphocytes.
Supplementary Figure 3 from Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of Nf1-Deficient Astrocytes
Authors: Banerjee Sutapa , Gianino Scott M. , Gao Feng , Christians Uwe , Gutmann David H.
Published: April 2023

Supplementary Figure 3 from Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of Nf1-Deficient Astrocytes
Supplementary Figure 2 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Authors: Elkins Kristi , Zheng Bing , Go MaryAnn , Slaga Dionysos , Du Changchun , Scales Suzie J. , Yu Shang-Fan , McBride Jacqueline , de Tute Ruth , Rawstron Andy , Jack Andrew S. , Ebens Allen , Polson Andrew G.
Published: April 2023

PDF file - 62KB, In vivo efficacy of anti-FcRL5-SPDB-DM4 in combination with bortezomib
Supplementary Figure 1 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Authors: Elkins Kristi , Zheng Bing , Go MaryAnn , Slaga Dionysos , Du Changchun , Scales Suzie J. , Yu Shang-Fan , McBride Jacqueline , de Tute Ruth , Rawstron Andy , Jack Andrew S. , Ebens Allen , Polson Andrew G.
Published: April 2023

PDF file - 282KB, In vivo efficacy of anti-FcRL5 ADCs with different linker-drugs
Supplementary Figure Legends 1-2 from Honokiol in Combination with Radiation Targets Notch Signaling to Inhibit Colon Cancer Stem Cells
Authors: Ponnurangam Sivapriya , Mammen Joshua M.V. , Ramalingam Satish , He Zhiyun , Zhang Youcheng , Umar Shahid , Subramaniam Dharmalingam , Anant Shrikant
Published: April 2023

PDF file - 61K
Supplementary Figure Legend from Human Monoclonal Antibodies Targeting Nonoverlapping Epitopes on Insulin-like Growth Factor II as a Novel Type of Candidate Cancer Therapeutics
Authors: Chen Weizao , Feng Yang , Zhao Qi , Zhu Zhongyu , Dimitrov Dimiter S.
Published: April 2023

PDF file, 62KB.
Supplementary Table 1 from A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
Authors: Visnyei Koppany , Onodera Hideyuki , Damoiseaux Robert , Saigusa Kuniyasu , Petrosyan Syuzanna , De Vries David , Ferrari Denise , Saxe Jonathan , Panosyan Eduard H. , Masterman-Smith Michael , Mottahedeh Jack , Bradley Kenneth A. , Huang Jing , Sabatti Chiara , Nakano Ichiro , Kornblum Harley I.
Published: April 2023

PDF File - (32K) - GSC-enriched GBM samples form tumors after transplantation into immunodeficient mice
Supplementary Table 1 from Triggering Fbw7-Mediated Proteasomal Degradation of c-Myc by Oridonin Induces Cell Growth Inhibition and Apoptosis
Authors: Huang Hui-Lin , Weng Heng-You , Wang Lu-Qin , Yu Chun-Hong , Huang Qiao-Juan , Zhao Pan-Pan , Wen Jun-Zhi , Zhou Hui , Qu Liang-Hu
Published: April 2023

PDF file - 42K, Primers sequences for RT-PCR and qRT-PCR.
Supplementary Materials and Methods from Triggering Fbw7-Mediated Proteasomal Degradation of c-Myc by Oridonin Induces Cell Growth Inhibition and Apoptosis
Authors: Huang Hui-Lin , Weng Heng-You , Wang Lu-Qin , Yu Chun-Hong , Huang Qiao-Juan , Zhao Pan-Pan , Wen Jun-Zhi , Zhou Hui , Qu Liang-Hu
Published: April 2023

PDF file - 83K, description on the methods used in Supplementary Table S3.
Supplementary Figure Legends 1-3 from Linear Chain PEGylated Recombinant Bacillus Thiaminolyticus Thiaminase I Enzyme Has Growth Inhibitory Activity against Lymphoid Leukemia Cell Lines
Authors: Daily Abigail , Liu Shuqian , Bae Younsoo , Bhatnagar Saloni , Moscow Jeffrey A.
Published: April 2023

PDF file - 41K
Supplementary Table 2 from Ovarian Cancer Stem Cell–Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2
Authors: Rizzo Siân , Hersey Jenny M. , Mellor Paul , Dai Wei , Santos-Silva Alessandra , Liber Daniel , Luk Louisa , Titley Ian , Carden Craig P , Box Garry , Hudson David L. , Kaye Stanley B. , Brown Robert
Published: April 2023

Supplementary Table 2 from Ovarian Cancer Stem Cell–Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2
Supplementary Figure 3 from Targeting Sarcoplasmic/Endoplasmic Reticulum Ca2+-ATPase 2 by Curcumin Induces ER Stress-Associated Apoptosis for Treating Human Liposarcoma
Authors: Wang Lu , Wang Lingxian , Song Ran , Shen Yan , Sun Yang , Gu Yanhong , Shu Yongqian , Xu Qiang
Published: April 2023

Supplementary Figure 3 from Targeting Sarcoplasmic/Endoplasmic Reticulum Ca2+-ATPase 2 by Curcumin Induces ER Stress-Associated Apoptosis for Treating Human Liposarcoma
Supplementary Figure 2 from Targeting Sarcoplasmic/Endoplasmic Reticulum Ca2+-ATPase 2 by Curcumin Induces ER Stress-Associated Apoptosis for Treating Human Liposarcoma
Authors: Wang Lu , Wang Lingxian , Song Ran , Shen Yan , Sun Yang , Gu Yanhong , Shu Yongqian , Xu Qiang
Published: April 2023

Supplementary Figure 2 from Targeting Sarcoplasmic/Endoplasmic Reticulum Ca2+-ATPase 2 by Curcumin Induces ER Stress-Associated Apoptosis for Treating Human Liposarcoma
Supplementary Table 1, Supplementary Figures 1-2 from Digitoxin-Induced Cytotoxicity in Cancer Cells Is Mediated through Distinct Kinase and Interferon Signaling Networks
Authors: Prassas Ioannis , Karagiannis George S. , Batruch Ihor , Dimitromanolakis Apostolos , Datti Alessandro , Diamandis Eleftherios P.
Published: April 2023

PDF File (50K)
Supplementary Figure 1 from Targeting Sarcoplasmic/Endoplasmic Reticulum Ca2+-ATPase 2 by Curcumin Induces ER Stress-Associated Apoptosis for Treating Human Liposarcoma
Authors: Wang Lu , Wang Lingxian , Song Ran , Shen Yan , Sun Yang , Gu Yanhong , Shu Yongqian , Xu Qiang
Published: April 2023

Supplementary Figure 1 from Targeting Sarcoplasmic/Endoplasmic Reticulum Ca2+-ATPase 2 by Curcumin Induces ER Stress-Associated Apoptosis for Treating Human Liposarcoma
Supplementary Table 2 from Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Krüppel-like Factor 5 Expression by Ultrahigh-Throughput Screening
Authors: Bialkowska Agnieszka B. , Crisp Melissa , Bannister Thomas , He Yuanjun , Chowdhury Sarwat , Schürer Stephan , Chase Peter , Spicer Timothy , Madoux Franck , Tian Chenlu , Hodder Peter , Zaharevitz Daniel , Yang Vincent W.
Published: April 2023

PDF file - 202K
Supplementary Figure Legends 1-9, Tables 1-2 from Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Krüppel-like Factor 5 Expression by Ultrahigh-Throughput Screening
Authors: Bialkowska Agnieszka B. , Crisp Melissa , Bannister Thomas , He Yuanjun , Chowdhury Sarwat , Schürer Stephan , Chase Peter , Spicer Timothy , Madoux Franck , Tian Chenlu , Hodder Peter , Zaharevitz Daniel , Yang Vincent W.
Published: April 2023

PDF file - 71K
Supplementary Methods, Figures 1-2 from Identification of a Natural Compound by Cell-Based Screening That Enhances Interferon Regulatory Factor-1 Activity and Causes Tumor Suppression
Authors: Gao Jinbo , Wang Yujun , Xing Quanhua , Yan Jin , Senthil Maheswari , Akmal Yasir , Kowolik Claudia M. , Kang Julia , Lu David M. , Zhao Ming , Lin Zhixiu , Cheng Christopher H.K. , Yip M.L. Richard , Yim John H.
Published: April 2023

PDF file - 62.6K
Supplementary Figure 6 from Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Krüppel-like Factor 5 Expression by Ultrahigh-Throughput Screening
Authors: Bialkowska Agnieszka B. , Crisp Melissa , Bannister Thomas , He Yuanjun , Chowdhury Sarwat , Schürer Stephan , Chase Peter , Spicer Timothy , Madoux Franck , Tian Chenlu , Hodder Peter , Zaharevitz Daniel , Yang Vincent W.
Published: April 2023

PDF file - 57K
Supplementary Figure 5 from Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β Family Traps
Authors: Zwaagstra John C. , Sulea Traian , Baardsnes Jason , Lenferink Anne E.G. , Collins Cathy , Cantin Christiane , Paul-Roc Béatrice , Grothe Suzanne , Hossain Sazzad , Richer Louis-Philippe , L'Abbé Denis , Tom Roseanne , Cass Brian , Durocher Yves , O'Connor-McCourt Maureen D.
Published: April 2023

PDF file, 293KB, Quantification of proliferating cells in 4T1 tumors.
Supplementary Figure 4 from Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Krüppel-like Factor 5 Expression by Ultrahigh-Throughput Screening
Authors: Bialkowska Agnieszka B. , Crisp Melissa , Bannister Thomas , He Yuanjun , Chowdhury Sarwat , Schürer Stephan , Chase Peter , Spicer Timothy , Madoux Franck , Tian Chenlu , Hodder Peter , Zaharevitz Daniel , Yang Vincent W.
Published: April 2023

PDF file - 365K
Supplementary Figure 3 from Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β Family Traps
Authors: Zwaagstra John C. , Sulea Traian , Baardsnes Jason , Lenferink Anne E.G. , Collins Cathy , Cantin Christiane , Paul-Roc Béatrice , Grothe Suzanne , Hossain Sazzad , Richer Louis-Philippe , L'Abbé Denis , Tom Roseanne , Cass Brian , Durocher Yves , O'Connor-McCourt Maureen D.
Published: April 2023

PDF file, 297KB, TGF-B1 neutralization using a (TBRII)2 trap having a natural or artificial linker sequence.
Supplementary Figure 1 from Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β Family Traps
Authors: Zwaagstra John C. , Sulea Traian , Baardsnes Jason , Lenferink Anne E.G. , Collins Cathy , Cantin Christiane , Paul-Roc Béatrice , Grothe Suzanne , Hossain Sazzad , Richer Louis-Philippe , L'Abbé Denis , Tom Roseanne , Cass Brian , Durocher Yves , O'Connor-McCourt Maureen D.
Published: April 2023

PDF file, 832KB, Schematics and molecular models of single-chain activin and BMP traps.
Supplementary Tables 1-2 from Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
Authors: Sunaga Noriaki , Shames David S. , Girard Luc , Peyton Michael , Larsen Jill E. , Imai Hisao , Soh Junichi , Sato Mitsuo , Yanagitani Noriko , Kaira Kyoichi , Xie Yang , Gazdar Adi F. , Mori Masatomo , Minna John D.
Published: April 2023

Supplementary Tables 1-2 from Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
Supplementary Table 1 from Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models
Authors: Wong Maureen , Tan Nguyen , Zha Jiping , Peale Franklin V. , Yue Peng , Fairbrother Wayne J. , Belmont Lisa D.
Published: April 2023

PDF file - 69K, H Score and Clinical Features.
Supplementary Figure 2 from Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models
Authors: Wong Maureen , Tan Nguyen , Zha Jiping , Peale Franklin V. , Yue Peng , Fairbrother Wayne J. , Belmont Lisa D.
Published: April 2023

PDF file - 680K, Overall Survival and Bcl-xL H Score.
Supplementary Figures 1-4 from Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
Authors: Sunaga Noriaki , Shames David S. , Girard Luc , Peyton Michael , Larsen Jill E. , Imai Hisao , Soh Junichi , Sato Mitsuo , Yanagitani Noriko , Kaira Kyoichi , Xie Yang , Gazdar Adi F. , Mori Masatomo , Minna John D.
Published: April 2023

Supplementary Figures 1-4 from Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
Supplementary Figures 1-3 from Levels of p27 Sensitize to Dual PI3K/mTOR Inhibition
Authors: Lee Misu , Theodoropoulou Marily , Graw Jochen , Roncaroli Federico , Zatelli Maria Chiara , Pellegata Natalia S.
Published: April 2023

PDF file - 270K
Supplementary Table 1 from A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
Authors: Hidalgo Manuel , Bruckheimer Elizabeth , Rajeshkumar N.V. , Garrido-Laguna Ignacio , De Oliveira Elizabeth , Rubio-Viqueira Belen , Strawn Steven , Wick Michael J. , Martell James , Sidransky David
Published: April 2023

Supplementary Table 1 from A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
Supplementary Table 5 from An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B
Authors: Winter Georg E. , Rix Uwe , Lissat Andrej , Stukalov Alexey , Müllner Markus K. , Bennett Keiryn L. , Colinge Jacques , Nijman Sebastian M. , Kubicek Stefan , Kovar Heinrich , Kontny Udo , Superti-Furga Giulio
Published: April 2023

XLS file - 11K
Supplementary Table 3 from An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B
Authors: Winter Georg E. , Rix Uwe , Lissat Andrej , Stukalov Alexey , Müllner Markus K. , Bennett Keiryn L. , Colinge Jacques , Nijman Sebastian M. , Kubicek Stefan , Kovar Heinrich , Kontny Udo , Superti-Furga Giulio
Published: April 2023

XLS file - 24K
Supplementary Figure Legends 1-5, Table Legends 1-5 from An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B
Authors: Winter Georg E. , Rix Uwe , Lissat Andrej , Stukalov Alexey , Müllner Markus K. , Bennett Keiryn L. , Colinge Jacques , Nijman Sebastian M. , Kubicek Stefan , Kovar Heinrich , Kontny Udo , Superti-Furga Giulio
Published: April 2023

PDF file - 69K
Supplementary Figure Legend from Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
Authors: Liu Fang , Korc Murray
Published: April 2023

PDF file, 94K.
Supplementary Figure 4 from An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B
Authors: Winter Georg E. , Rix Uwe , Lissat Andrej , Stukalov Alexey , Müllner Markus K. , Bennett Keiryn L. , Colinge Jacques , Nijman Sebastian M. , Kubicek Stefan , Kovar Heinrich , Kontny Udo , Superti-Furga Giulio
Published: April 2023

PDF file - 46K
Supplementary Figure 6 from Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
Authors: Liu Fang , Korc Murray
Published: April 2023

PDF file, 4534K, Effects of PD-0332991 and SB-505124 on growth in 3-D culture and in a clonogenic assay.
Supplementary Figure 4 from Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
Authors: Liu Fang , Korc Murray
Published: April 2023

PDF file, 1109K, Effects of cdk4 and cdk6 knockdown on EMT in PANC-1 cells.
Supplementary Figure 2 from Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
Authors: Liu Fang , Korc Murray
Published: April 2023

PDF file, 805K, Effects of PD-0332991 incubation on gene expression.
Supplementary Table 1 from Targeting the Intracellular MUC1 C-terminal Domain Inhibits Proliferation and Estrogen Receptor Transcriptional Activity in Lung Adenocarcinoma Cells
Authors: Klinge Carolyn M. , Radde Brandie N. , Imbert-Fernandez Yoannis , Teng Yun , Ivanova Margarita M. , Abner Sabra M. , Martin Alexandra L.
Published: April 2023

PDF file - 59K
Supplementary Figure Legends 1-3 from Integrin α6high Cell Population Functions as an Initiator in Tumorigenesis and Relapse of Human Liposarcoma
Authors: Wang Lu , Wang Lingxian , Gu Yanhong , Shu Yongqian , Shen Yan , Xu Qiang
Published: April 2023

PDF file - 51K
Supplementary Figure Legend from High-Risk Endometrial Carcinoma Profiling Identifies TGF-β1 as a Key Factor in the Initiation of Tumor Invasion
Authors: Muinelo-Romay Laura , Colas Eva , Barbazan Jorge , Alonso-Alconada Lorena , Alonso-Nocelo Marta , Bouso Marta , Curiel Teresa , Cueva Juan , Anido Urbano , Forteza Jeronimo , Gil-Moreno Antonio , Reventos Jaume , Lopez-Lopez Rafael , Abal Miguel
Published: April 2023

Supplementary Figure Legend from High-Risk Endometrial Carcinoma Profiling Identifies TGF-β1 as a Key Factor in the Initiation of Tumor Invasion
Supplementary Figure 2 from Targeting the Microtubular Network as a New Antimyeloma Strategy
Authors: Feng Rentian , Li Shirong , Lu Caisheng , Andreas Carrie , Stolz Donna B. , Mapara Markus Y. , Lentzsch Suzanne
Published: April 2023

PDF file - 199K, Nocodazole induces microtubular network disarray and morphologic elongation in multiple myeloma cells.
Supplementary Figure Legend from Restitution of Tumor Suppressor MicroRNAs Using a Systemic Nanovector Inhibits Pancreatic Cancer Growth in Mice
Authors: Pramanik Dipankar , Campbell Nathaniel R. , Karikari Collins , Chivukula Raghu , Kent Oliver A. , Mendell Joshua T. , Maitra Anirban
Published: April 2023

Supplementary Figure Legend from Restitution of Tumor Suppressor MicroRNAs Using a Systemic Nanovector Inhibits Pancreatic Cancer Growth in Mice
Supplementary Figure Legend from A Locked, Dimeric CXCL12 Variant Effectively Inhibits Pulmonary Metastasis of CXCR4-Expressing Melanoma Cells Due to Enhanced Serum Stability
Authors: Takekoshi Tomonori , Ziarek Joshua J. , Volkman Brian F. , Hwang Sam T.
Published: April 2023

PDF file, 62K.
Supplementary Video 7 from Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01
Authors: On Kin Fan , Chen Yue , Tang Ma Hoi , Chow Jeremy P.H. , Poon Randy Y.C.
Published: April 2023

Supplementary Video 7 from Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01
Supplementary Video 3 from Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01
Authors: On Kin Fan , Chen Yue , Tang Ma Hoi , Chow Jeremy P.H. , Poon Randy Y.C.
Published: April 2023

Supplementary Video 3 from Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01
Supplementary Video 2 from Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01
Authors: On Kin Fan , Chen Yue , Tang Ma Hoi , Chow Jeremy P.H. , Poon Randy Y.C.
Published: April 2023

Supplementary Video 2 from Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01
Supplementary Figures 1-8 from Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01
Authors: On Kin Fan , Chen Yue , Tang Ma Hoi , Chow Jeremy P.H. , Poon Randy Y.C.
Published: April 2023

Supplementary Figures 1-8 from Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01
Supplementary Figures 1-11 from 2-Methoxy-5-Amino-N-Hydroxybenzamide Sensitizes Colon Cancer Cells to TRAIL-Induced Apoptosis by Regulating Death Receptor 5 and Survivin Expression
Authors: Stolfi Carmine , Caruso Roberta , Franzè Eleonora , Rizzo Angelamaria , Rotondi Angela , Monteleone Ivan , Fantini Massimo Claudio , Pallone Francesco , Monteleone Giovanni
Published: April 2023

PDF file - 996K
Supplementary Figure 4 from Targeting Tyrosine Phosphorylation of PCNA Inhibits Prostate Cancer Growth
Authors: Zhao Huajun , Lo Yuan-Hung , Ma Li , Waltz Susan E. , Gray Jerilyn K. , Hung Mien-Chie , Wang Shao-Chun
Published: April 2023

Supplementary Figure 4 from Targeting Tyrosine Phosphorylation of PCNA Inhibits Prostate Cancer Growth
Supplement 5 from Melanoma Prognosis: A REMARK-Based Systematic Review and Bioinformatic Analysis of Immunohistochemical and Gene Microarray Studies
Authors: Schramm Sarah-Jane , Mann Graham J.
Published: April 2023

Supplement 5 from Melanoma Prognosis: A REMARK-Based Systematic Review and Bioinformatic Analysis of Immunohistochemical and Gene Microarray Studies
Supplementary Figure 1 from Targeting Tyrosine Phosphorylation of PCNA Inhibits Prostate Cancer Growth
Authors: Zhao Huajun , Lo Yuan-Hung , Ma Li , Waltz Susan E. , Gray Jerilyn K. , Hung Mien-Chie , Wang Shao-Chun
Published: April 2023

Supplementary Figure 1 from Targeting Tyrosine Phosphorylation of PCNA Inhibits Prostate Cancer Growth
Supplement 3 from Melanoma Prognosis: A REMARK-Based Systematic Review and Bioinformatic Analysis of Immunohistochemical and Gene Microarray Studies
Authors: Schramm Sarah-Jane , Mann Graham J.
Published: April 2023

Supplement 3 from Melanoma Prognosis: A REMARK-Based Systematic Review and Bioinformatic Analysis of Immunohistochemical and Gene Microarray Studies
Supplementary Figure 4 from Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
Authors: Soares Daniele G. , Machado Miriana S. , Rocca Céline J. , Poindessous Virginie , Ouaret Djamila , Sarasin Alain , Galmarini Carlos M. , Henriques João A.P. , Escargueil Alexandre E. , Larsen Annette K.
Published: April 2023

Supplementary Figure 4 from Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
Supplementary Figure 3 from Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
Authors: Soares Daniele G. , Machado Miriana S. , Rocca Céline J. , Poindessous Virginie , Ouaret Djamila , Sarasin Alain , Galmarini Carlos M. , Henriques João A.P. , Escargueil Alexandre E. , Larsen Annette K.
Published: April 2023

Supplementary Figure 3 from Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
Supplement 1 from Melanoma Prognosis: A REMARK-Based Systematic Review and Bioinformatic Analysis of Immunohistochemical and Gene Microarray Studies
Authors: Schramm Sarah-Jane , Mann Graham J.
Published: April 2023

Supplement 1 from Melanoma Prognosis: A REMARK-Based Systematic Review and Bioinformatic Analysis of Immunohistochemical and Gene Microarray Studies
Supplementary Figures 1 - 4 from Micelle-Encapsulated Thiostrepton as an Effective Nanomedicine for Inhibiting Tumor Growth and for Suppressing FOXM1 in Human Xenografts
Authors: Wang Ming , Gartel Andrei L.
Published: April 2023

PDF file - 209KB
Supplementary Figure 1, Tables 2-7 from Low-Dose Fractionated Radiation Potentiates the Effects of Cisplatin Independent of the Hyper-Radiation Sensitivity in Human Lung Cancer Cells
Authors: Gupta Seema , Koru-Sengul Tulay , Arnold Susanne M. , Devi Gayathri R. , Mohiuddin Mohammed , Ahmed Mansoor M.
Published: April 2023

PDF file - 137K
Supplementary Figure Legends 1-2 from The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors
Authors: Floris Giuseppe , Debiec-Rychter Maria , Wozniak Agnieszka , Stefan Cristiana , Normant Emmanuel , Faa Gavino , Machiels Kathleen , Vanleeuw Ulla , Sciot Raf , Schöffski Patrick
Published: April 2023

PDF file - 78K
Supplementary Figure 1 from The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors
Authors: Floris Giuseppe , Debiec-Rychter Maria , Wozniak Agnieszka , Stefan Cristiana , Normant Emmanuel , Faa Gavino , Machiels Kathleen , Vanleeuw Ulla , Sciot Raf , Schöffski Patrick
Published: April 2023

PDF file - 271K
Supplementary Methods from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
Authors: Nebbioso Angela , Pereira Raquel , Khanwalkar Harshal , Matarese Filomena , García-Rodríguez José , Miceli Marco , Logie Colin , Kedinger Valerie , Ferrara Felicetto , Stunnenberg Hendrik G. , de Lera Angel R. , Gronemeyer Hinrich , Altucci Lucia
Published: April 2023

PDF file - 247K
Supplementary Figure Legends 1-4 from Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β
Authors: Bielen Aleksandra , Perryman Lara , Box Gary M. , Valenti Melanie , de Haven Brandon Alexis , Martins Vanessa , Jury Alexa , Popov Sergey , Gowan Sharon , Jeay Sebastien , Raynaud Florence I. , Hofmann Francesco , Hargrave Darren , Eccles Suzanne A. , Jones Chris
Published: April 2023

Supplementary Figure Legends 1-4 from Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β
Supplementary Figure 4 from Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β
Authors: Bielen Aleksandra , Perryman Lara , Box Gary M. , Valenti Melanie , de Haven Brandon Alexis , Martins Vanessa , Jury Alexa , Popov Sergey , Gowan Sharon , Jeay Sebastien , Raynaud Florence I. , Hofmann Francesco , Hargrave Darren , Eccles Suzanne A. , Jones Chris
Published: April 2023

Supplementary Figure 4 from Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β
Supplementary Figure 2 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
Authors: Nebbioso Angela , Pereira Raquel , Khanwalkar Harshal , Matarese Filomena , García-Rodríguez José , Miceli Marco , Logie Colin , Kedinger Valerie , Ferrara Felicetto , Stunnenberg Hendrik G. , de Lera Angel R. , Gronemeyer Hinrich , Altucci Lucia
Published: April 2023

PDF file - 124K
Supplementary Figure 3 from Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β
Authors: Bielen Aleksandra , Perryman Lara , Box Gary M. , Valenti Melanie , de Haven Brandon Alexis , Martins Vanessa , Jury Alexa , Popov Sergey , Gowan Sharon , Jeay Sebastien , Raynaud Florence I. , Hofmann Francesco , Hargrave Darren , Eccles Suzanne A. , Jones Chris
Published: April 2023

Supplementary Figure 3 from Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β
Supplementary Figure 1 from Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β
Authors: Bielen Aleksandra , Perryman Lara , Box Gary M. , Valenti Melanie , de Haven Brandon Alexis , Martins Vanessa , Jury Alexa , Popov Sergey , Gowan Sharon , Jeay Sebastien , Raynaud Florence I. , Hofmann Francesco , Hargrave Darren , Eccles Suzanne A. , Jones Chris
Published: April 2023

Supplementary Figure 1 from Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β
Supplementary Table 4 from Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer
Authors: Kim Mickey K. , Osada Takuya , Barry William T. , Yang Xiao Yi , Freedman Jennifer A. , Tsamis Katherine A. , Datto Michael , Clary Bryan M. , Clay Timothy , Morse Michael A. , Febbo Philip G. , Lyerly H. Kim , Hsu David S.
Published: April 2023

PDF file - 47K, Corresponding class and predicted response to oxaliplatin for patient derived colorectal cancer explants.
Supplementary Table 1 from A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma
Authors: Torres Sofía , Lorente Mar , Rodríguez-Fornés Fátima , Hernández-Tiedra Sonia , Salazar María , García-Taboada Elena , Barcia Juan , Guzmán Manuel , Velasco Guillermo
Published: April 2023

Supplementary Table 1 from A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma
Supplementary Table 2 from Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer
Authors: Kim Mickey K. , Osada Takuya , Barry William T. , Yang Xiao Yi , Freedman Jennifer A. , Tsamis Katherine A. , Datto Michael , Clary Bryan M. , Clay Timothy , Morse Michael A. , Febbo Philip G. , Lyerly H. Kim , Hsu David S.
Published: April 2023

PDF file - 61K, Gene List of Oxaliplatin Sensitivity Signature.
Supplementary Figure Legends 1-2 from Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer
Authors: Kim Mickey K. , Osada Takuya , Barry William T. , Yang Xiao Yi , Freedman Jennifer A. , Tsamis Katherine A. , Datto Michael , Clary Bryan M. , Clay Timothy , Morse Michael A. , Febbo Philip G. , Lyerly H. Kim , Hsu David S.
Published: April 2023

PDF file - 67K
Supplementary Figure S5ABC from Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Authors: Raina Deepak , Kosugi Michio , Ahmad Rehan , Panchamoorthy Govind , Rajabi Hasan , Alam Maroof , Shimamura Takeshi , Shapiro Geoffrey I. , Supko Jeffrey , Kharbanda Surender , Kufe Donald
Published: April 2023

Supplementary Figure S5ABC from Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Supplementary Figure S3AB from Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Authors: Raina Deepak , Kosugi Michio , Ahmad Rehan , Panchamoorthy Govind , Rajabi Hasan , Alam Maroof , Shimamura Takeshi , Shapiro Geoffrey I. , Supko Jeffrey , Kharbanda Surender , Kufe Donald
Published: April 2023

Supplementary Figure S3AB from Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells